Evidence map›Paper›PMID 33682858›Full record

ArticleJournal of visualized experiments : JoVE2021

Stereotaxic Intracranial Delivery of Chemicals, Proteins or Viral Vectors to Study Parkinson's Disease.

Natalie Landeck, Melissa Conti Mazza, Megan Duffy, Christopher Bishop, Caryl E Sortwell, Mark R Cookson

Open access · greenAbstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Extracellular Vesicles for Disease Treatment.International journal of nanomedicine · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Natalie LandeckCell Biology and Gene Expression Section, National Institute on Aging, National Institutes of Health; natalie.landeck@gmail.com.
Melissa Conti MazzaCell Biology and Gene Expression Section, National Institute on Aging, National Institutes of Health.
Megan DuffyCell Biology and Gene Expression Section, National Institute on Aging, National Institutes of Health.
Christopher BishopBehavioral Neuroscience Program, Department of Psychology, Binghamton University.
Caryl E SortwellDepartment of Translational Neuroscience, Mercy Health Hauenstein Neuroscience Medical Center, Michigan State University.
Mark R CooksonCell Biology and Gene Expression Section, National Institute on Aging, National Institutes of Health.
Institute on Aging · USBinghamton University · USMercy Health · USNational Institute on Aging · USNational Institutes of Health · US

Funding

Alpha Synuclein, cellular dysfunction and Parkinson diseaseZIAAG000939 · NIA · NATIONAL INSTITUTE ON AGING · PI COOKSON, MARK · 2009 to 2025
$12.7M
Rodent Behavioral Core: The Analysis of BehaviorZICMH002952 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI CHUDASAMA, YOGITA · 2016 to 2025
$7.5M
The Rat Pre-Formed Alpha-Synuclein Fibril Model of Parkinson's DiseaseR33NS099416 · NINDS · MICHIGAN STATE UNIVERSITY · PI SORTWELL, CARYL E · 2018 to 2019
$899k
The Rat Pre-Formed Alpha-Synuclein Fibril Model of Parkinson's DiseaseR21NS099416 · NINDS · MICHIGAN STATE UNIVERSITY · PI SORTWELL, CARYL E · 2017 to 2017
$398k
Intramural NIH HHS ZIA AG000939Intramural NIH HHS ZIC MH002952NINDS NIH HHS R21 NS099416NINDS NIH HHS R33 NS099416
6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive disorder traditionally defined by resting tremor and akinesia, primarily due to loss of dopaminergic neurons in the substantia nigra. Affected brain areas display intraneuronal fibrillar inclusions consisting mainly of alpha-synuclein (asyn) proteins. No animal model thus far has recapitulated all characteristics of this disease. Here, we describe the use of stereotaxic injection to deliver chemicals, proteins, or viral vectors intracranially in order to mimic various aspects of PD. These methods are well-established and widely used throughout the PD field. Stereotaxic injections are incredibly flexible; they can be adjusted in concentration, age of animal used for injection, brain area targeted and in animal species used. Combinations of substances allow for rapid variations to assess treatments or alter severity of the pathology or behavioral deficits. By injecting toxins into the brain, we can mimic inflammation and/or a severe loss of dopaminergic neurons resulting in substantial motor phenotypes. Viral vectors can be used to transduce cells to mimic genetic or mechanistic aspects. Preformed fibrillar asyn injections best recapitulate the progressive phenotype over an extended period of time. Once these methods are established, it can be economical to generate a new model compared to creating a new transgenic line. However, this method is labor intensive as it requires 30 minutes to four hours per animal depending on the model used. Each animal will have a slightly different targeting and therefore create a diverse cohort which on one hand can be challenging to interpret results from; on the other hand, help mimic a more realistic diversity found in patients. Mistargeted animals can be identified using behavioral or imaging readouts, or only after being sacrificed leading to smallercohort size after the study has already been concluded. Overall, this method is a rudimentary but effective way to assess a diverse set of PD aspects.

Indexed as

Drug Delivery SystemsStereotaxic TechniquesAnesthesiaAnimalsBrainDisease Models, AnimalGenetic VectorsHumansMaleParkinson DiseasePostoperative CareViruses

Identifiers

PMID33682858
PMCPMC8981414
OpenAlexW3131083542

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.